

WO2004113314

Publication Title:

NOVEL BORONATE ESTERS

Abstract:

Abstract of WO2004113314

The present invention relates to optically active dihydroxy hexanoate derivatives, boronate esters of formula (IIa) which are useful intermediates for the synthesis of HMG-CoA enzyme inhibitors like atorvastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin. Ar = unsubstituted or substituted aryl or heteroaryl, R3 = alkyl from 1 to 8 carbons, aryl or aralkyl, R4 = O, OH, CN or a halogen and a = single bond or a double bond. Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/113314 A1

(51) International Patent Classification⁷: C07D 305/12,
C12P 17/02

(21) International Application Number:
PCT/IN2004/000175

(22) International Filing Date: 18 June 2004 (18.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
508/Mas/2003 23 June 2003 (23.06.2003) IN

(71) Applicant (for all designated States except US): BIOCON LIMITED [IN/IN]; 20th Km Hosur Road, Electronics City P.O., Bangalore 561 229, Karnataka (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MELARKODE, Ramakrishnan [IN/IN]; Biocon Limited, 20th Km Hosur Road, Electronics City P.O., Bangalore 561 229, Karnataka (IN). TIWARI, Sanjay [IN/IN]; Biocon Limited, 20th Km Hosur Road, Electronics City P.O., Bangalore 561 229, Karnataka (IN). SURYANARAYAN, Shrikumar [IN/IN]; Biocon Limited, 20th Km Hosur Road, Electronics City P.O., Bangalore 561 229, Karnataka (IN). KHEDKAR, Anand [IN/IN]; Biocon Limited, 20th Km Hosur Road, Electronics City P.O., Bangalore 561 229, Karnataka (IN).

(74) Agents: ANAND, Pravin et al.; Anand and Anand Advocates, B-41 Nizamuddin East, New Delhi 110 013 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW), ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, IIR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW), ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)


— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

{Continued on next page}

(54) Title: NOVEL BORONATE ESTERS



WO 2004/113314 A1

(57) Abstract: The present invention relates to optically active dihydroxy hexanoate derivatives, boronate esters of formula (IIIa) which are useful intermediates for the synthesis of HMG-CoA enzyme inhibitors like atorvastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin. Ar = unsubstituted or substituted aryl or heteroaryl, R3 = alkyl from 1 to 8 carbons, aryl or aralkyl, R4 = O, OH, CN or a halogen and a = single bond or a double bond.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

5 TITLE OF THE INVENTION


Novel Boronate esters

FIELD OF THE INVENTION


The present invention relates to optically active dihydroxy hexanoate derivatives of formula IIa and more particularly to
 10 compounds of formula II which are useful intermediates for the synthesis of HMG-CoA enzyme inhibitors like atorvastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin.

BACKGROUND OF THE INVENTION


Esters and derivatives of the formula 1,



where R_1 and R_2 are independently chosen alkyl of one to three carbons and R_3 is alkyl of from 1 to 8 carbon atoms,
 alternatively compounds of formula 1a,



20 wherein R_1 and R_2 are independently chosen from alkyl of one to three carbons, phenyl or R_1 and R_2 taken together as - $(\text{CH}_2)_n$ - wherein n is 4 or 5 and R_3 is alkyl of from 1 to 8 carbon atoms and also compounds of Formula 1b



25 wherein R_1 and R_2 are alkyl of from 1-5 carbons and R_3 is as defined above is a valuable structural element for synthesizing

- 5 compounds, which are known as anti-hypercholesterolemic agents having an inhibitory effect on HMG-CoA reductase.

EP 0 319 847 describes a process for the preparation of compounds of formula 1 starting from L-Malic acid. This process, however, suffers from the fact that the process is not industrially 10 scalable and also possesses purification problems due to the non-crystalline nature of the intermediates.

US 5,399,722 describe a process starting from commercially available ethyl ω -chloroacetoacetate or its benzyloxy derivative. The disadvantages of this process are that a stereo selective reduction 15 using a costly ruthenium-BINAP catalyst is employed and the desired compound of formula 1 is obtained in six steps.

US 5,481,009 describe a process starting from 4-phenyl-3-butenoic acid in about 5 steps. The process uses expensive materials like - N, O-Dimethyl hydroxylamine and hazardous steps 20 (ozonolysis) to obtain the desired product.

US 5,998,633 describes a process for the preparation of protected esters of 3,4-dihydroxy butyric acid from a carbohydrate moiety which is transformed into the desired 3,4-dihydroxy butanoic acid derivatives in about 4 steps. The 3,4-dihydroxy 25 butanoic acid derivative is then functionalized into compounds of formula I involving a multiple number of steps.


US 6,140,527 describes a process for producing butyric acid derivatives starting from a butene derivative followed by reaction with an addition reagent capable of adding across the double bond. 30 However, this procedure does not afford chiral molecules and hence necessitates the need for a resolution step.

5 EP 0 104 750 describes a process for the preparation of 5-hydroxy-3-oxo pentanoic acid derivatives by alkylation of 3-hydroxybutyrate derivatives. The derivatives mentioned in this patent are racemic molecules and thus necessitating a resolution step.

10 The objective of the present is to provide a simple and industrially scalable process for the preparation of derivatives of formula I starting from commercially available and inexpensive malic acid.


Summary of the invention

15 To achieve the said object the present invention provides a product of formula IIa and more particularly a compound of formula II



20

Formula IIa



25

Formula II

5 wherein


Ar = unsubstituted or substituted aryl or heteroaryl

R₃ = alkyl from 1 to 8 carbons, aryl or aralkyl

R₄ = O, OH, CN or a halogen and

10 a = single bond or double bond

The present invention also provides for a process for the manufacture of compounds of formula II




Ar = unsubstituted or substituted aryl or heteroaryl


15 R₃ = alkyl from 1 to 8 carbons, aryl or aralkyl

which comprises of:

(a) reacting compound of formula III with the anion of tertiary butyl acetate to give a compound of formula IV, where G is tetrahydropyranyl, tert-butyldimethyl silyl or trityl and R₃ is alkyl from 1 to 8 carbons, aryl or aralkyl,




Formula III



Formula IV


(b) subjecting compound of formula IV to reduction to give 25 a compound of formula V, where G is tetrahydropyranyl, tert-butyldimethyl silyl or trityl and R₃ is alkyl from 1 to 8 carbons, aryl or aralkyl,

5



Formula V


- (c) protecting the compound of formula V with ArB(OH)₂ to give a compound of formula VI, where Ar is unsubstituted or substituted aryl or heteroaryl, G is tetrahydropyranyl, tert-butylidimethyl silyl or trityl and R₃ is alkyl from 1 to 8 carbons, aryl or aralkyl, and
- !0



Formula VI

- (f) deprotection of the compound of formula VI using mild acid catalyst to give a compound of formula II.
Said ArB(OH)₂ is boronic acid.
- !5


- The compound of formula II is oxidized to a compound of formula VIII, where R₃ is alkyl from 1 to 8 carbons, aryl or aralkyl
and Ar is unsubstituted or substituted aryl or heteroaryl using
20 pyridinium chloro chromate or DMSO/oxalyl chloride.
- 20



Formula VIII

- The compound of formula II is further converted to a
25 compound of formula IX, where R₃ is alkyl from 1 to 8 carbons, aryl
or aralkyl, Ar is unsubstituted or substituted aryl or heteroaryl and
X is a halogen.
- 25


5



Formula IX

The compound of formula IX is further converted to a compound of formula VII, where R_3 is alkyl from 1 to 8 carbons, aryl or aralkyl, Ar is unsubstituted or substituted aryl or heteroaryl.

10



Formula VII

The product of formula IIa and more particularly of formula II are used in the synthesis of atorvastatin, cerivastatin, pitavastatin, fluvastatin or rosuvastatin.

15 Detailed Description of the invention

Compound of formula II serves as a good intermediate for the synthesis of important substrates, which are useful in the synthesis of statins. Compound of formula II can be converted into a facile leaving group by treating with tosyl chloride, methane 20 sulfonyl chloride and the resulting intermediate can be displaced with cyanide to give compounds of formula VII.

Compound of formula II can be converted to formula IX by reacting with aqueous HBr solution or by reaction with triphenyl phosphine and CBr_4 which is then converted to compound of 25 formula VII.

Compound of formula II can be oxidized using standard procedures to give a compound of formula VIII.

5 The present invention relates to optically active dihydroxy
hexanoate derivatives of formula IIa which are useful intermediates
for the synthesis of HMG-CoA enzyme inhibitors like atorvastatin,
cerivastatin, rosuvastatin, pitavastatin, fluvastatin.

10 The invention is further illustrated with examples below,
which are not intended to be limiting.

Example 1: Synthesis of methyl 4-triphenylmethoxy-3-hydroxybutyrate (Formula III)

To 25g of methyl 3,4-dihydroxybutanoate was added to
250ml of DCM and stirred to dissolve and 19.8g of pyridine was
15 charged and cooled to 0°C. 41.4g of trityl chloride was dissolved in
50ml of DMC and was added at 0-5°C for 15 min. The temperature
was allowed to rise to RT and was stirred at RT for 17h. Water
was added and the layers were separated. The organic layer was
washed with brine, dried and concentrated. The residue was
20 triturated with 25ml of cyclohexane and the product was purified to
give 15g of the pure product.

NMR (CDCl₃) : 4.25 (m, 1H), 3.6 (s, 3H), 3.15 (d, 2H), 2.5
(m, 2H), 7.2-7.4 (m, 15H)

Example 2: Synthesis of tert-butyl 6-triphenylmethoxy-5-hydroxy-3-oxohexanoate (Formula IV)

To 125ml of THF, 24g of diisopropylamine were charged and
was cooled to -15°C. 168ml of 1.2N n-BuLi was added at -15 to -
5°C and was stirred for 30min. 21.56g of tert-butyl acetate in 45ml
of THF which was pre-cooled to -45°C was added maintaining the
30 temperature between -45 to -25°C for 60min. Cool the reaction
mixture to -45°C and 30g of example-1 in THF was added over a

5 period of 20min and the stirring was continued at -25°C for 90min. Water was added and the layers were separated. The aqueous layer was extracted using EtOAc and the combined organic layers were washed with brine, water, dried and concentrated to give the title compound which was used as such for the next step.

10 **Example 3: Synthesis of tert-butyl 6-triphenylmethyloxy-3,5-dihydroxhexanoate (Formula V)**

To the crude material obtained in example-2, 150ml of THF was added followed by 15ml of MeOH and was chilled to -60°C. 26ml of MDEB (50% solution in THF) was added over a period of
15 20min and stirring was continued for a further 30min. The reaction mixture was cooled to -80°C and 5g of sodium borohydride was added in portions and the after completion of addition the reaction mixture was stirred for 5h at -78°C. Acetic acid was added to adjust the pH to 7 and water was added. The aqueous layer was extracted using EtOAc, washed with brine, dried and concentrated to give the title compound which was used as such for the next step.

20 **Example 4: Synthesis of tert-Butyl 6-triphenylmethyloxy-3,5-phenylboranatohexanoate (Formula VI)**

25 The crude product from example-3 was dissolved in 100ml of toluene and 5.6g of phenyl boronic acid was added. Water was removed by azeotropic distillation over a period of 3h. The reaction mixture was cooled to RT and toluene was removed under reduced pressure. 30ml of methanol was added and the precipitated solid
30 was filtered to give 10g of the title product.

5 **Example 5: Synthesis of tert-butyl 6-hydroxy-3,5-(phenylboranato)hexanoate (Formula II)**

To 5g of the product from example-4 20ml of DCM was added and was chilled to 0°C. 5ml of TFA was added and was stirred at 20°C for 6h. Water was separated and the organic layer 10 was washed with bicarbonate, brine, dried and concentrated to give the title product, which was purified by column chromatography.

NMR (CDCl₃) : 7.7-7.8 (m, 2H), 7.4-7.5 (m, 1H), 7.3-7.4 (m, 2H), 4.5 (m, 1H), 4.2 (m, 1H), 3.6 (m, 1H), 3.5 (m, 1H), 2.55 (m, 15 1H), 2.45 (m, 1H), 2.0 (m, 1H), 1.7 (m, 1H) 1.5 (s, 9H)






Example 6: Synthesis of tert-butyl 6-cyano-3,5-(phenylboranato)hexanoate (Formula VII)

5g of the product obtained from example 5 was taken in dichloromethane (50mL) and pyridine (10mL) was added. The 20 contents were cooled to -10°C and methanesulfonyl chloride (1 eq) was added drop wise. After 5-6 hours of stirring at 0°C, the contents were washed with bicarbonate, water and brine. The solvent was removed under reduced pressure to afford the O-methanesulfonyl derivative, which was used as such for the next 25 step.

The crude mesylate was taken in DMSO (5 vols.) and 1.5 equivalents of potassium cyanide was added. The contents were maintained at reflux for a period of 18-22h. DMSO was removed under reduced pressure and the contents were extracted using 30 ethyl acetate and was washed with bisulfite, brine and solvent was removed under reduced pressure to afford the desired product.


5 Example 7: Synthesis of t-butyl 6-oxo-3,5-phenylboranatohexanoate (Formula VIII)

4.3g of dimethylsulfoxide was added drop wise to a solution of 2.4ml of oxalyl chloride in 100ml of dichloromethane maintained at -78°C. The mixture was stirred at that temperature for a period 10 of 15min and 5g of the compound from example 5 dissolved in dichloromethane was added drop wise. After stirring for 15min, 17ml of triethyl amine was added and the reaction mixture was allowed to warm to ambient temperature in 2h period. Reaction mixture was concentrated and the residue was dissolved in water 15 and extracted using diethyl ether. Removal of solvent affords the title compound.


Formula I  R1 and R2 are alkyl 1 to 3 carbons R3 is alkyl from 1 to 8 carbons	Formula 1b  R1 and R2 are alkyl from 1 to 5 carbons R3 is alkyl from 1 to 8 carbons
Formula 1a  R1 and R2 are alkyl 1 to 3 carbons or taken together as -(CH2)n- where n is 4 or 5 R3 is alkyl from 1 to 8 carbons	Formula IIa  Ar = unsubstituted or substituted aryl or heteroaryl R3 = alkyl from 1 to 8 carbons, aryl or aralkyl R4 = OH, CN or X and a = single bond R4 = O and a = double bond
Formula II	Formula III 

<p>Ar = Unsubstituted or substituted aryl or heteroaryl and R3 is carbon from 1-8 atoms, aryl or aralkyl</p>	<p>G = tetrahydropyranyl, tert-butyldimethyl silyl, trityl</p>
<p>Formula IV</p> <p>G = tetrahydropyranyl, tert-butyldimethyl silyl, trityl and R3 = alkyl from 1 to 8 carbons, aryl or aralkyl</p>	<p>Formula V</p> <p>G = tetrahydropyranyl, tert-butyldimethyl silyl, trityl and R3 = alkyl from 1 to 8 carbons, aryl or aralkyl</p>
<p>Formula VI</p> <p>G = tetrahydropyranyl, tert-butyldimethyl silyl, trityl and Ar = Unsubstituted or substituted aryl or heteroaryl and R3 is carbon from 1-8 atoms, aryl or aralkyl</p>	<p>Formula VII</p> <p>Ar = Unsubstituted or substituted aryl or heteroaryl and R3 is carbon from 1-8 atoms, aryl or aralkyl</p>
<p>Formula VIII</p> <p>Ar = Unsubstituted or substituted aryl or heteroaryl and R3 is carbon from 1-8 atoms, aryl or aralkyl</p>	<p>Formula IX</p> <p>Ar = Unsubstituted or substituted aryl or heteroaryl and R3 is carbon from 1-8 atoms, aryl or aralkyl and x = halogen</p>


5

Scheme - 1**Scheme - 2**


5 Scheme - 3



Scheme - 4




Scheme - 5




10

Scheme - 6



Scheme - 7




15

12

5 We claim:

1. The product of formula IIa



wherein

10 Ar = unsubstituted or substituted aryl or heteroaryl


R₃ = alkyl from 1 to 8 carbons, aryl or aralkyl

R₄ = O, OH, CN or a halogen and

a = single bond or double bond

15

2. The product as claimed in claim 1 wherein said product is a compound of formula II




wherein

20 Ar = unsubstituted or substituted aryl or heteroaryl

R₃ = alkyl from 1 to 8 carbons, aryl or aralkyl

5 3. A process for the manufacture of compounds of formula II




Ar = unsubstituted or substituted aryl or heteroaryl


R₃ = alkyl from 1 to 8 carbons, aryl or aralkyl

which comprises of:

- 10 (a) reacting compound of formula III with the anion of tertiary butyl acetate to give a compound of formula IV, where G is tetrahydropyranyl, tert-butyldimethyl silyl or trityl and R₃ is alkyl from 1 to 8 carbons, aryl or aralkyl,




15 Formula III



Formula IV


- 15 (b) subjecting compound of formula IV to reduction to give a compound of formula V, where G is tetrahydropyranyl, tert-butyldimethyl silyl or trityl and R₃ is alkyl from 1 to 8 carbons, aryl or aralkyl,



20 Formula V

- 25 (c) protecting the compound of formula V with ArB(OH)₂ to give a compound of formula VI, where Ar is unsubstituted or substituted aryl or heteroaryl, G is tetrahydropyranyl, tert-


5 butyldimethyl silyl or trityl and R₃ is alkyl from 1 to 8
carbons, aryl or aralkyl, and



Formula VI


(f) deprotection of the compound of formula VI using mild
10 acid catalyst to give a compound of formula II.

4. A process as claimed in claim 3 wherein ArB(OH)₂ is boronic acid.
5. A process as claimed in claim 3 wherein compound of formula II is oxidized to a compound of formula VIII, where R₃ is alkyl from 15 1 to 8 carbons, aryl or aralkyl and Ar is unsubstituted or substituted aryl or heteroaryl using pyridinium chloro chromate or DMSO/oxalyl chloride.




Formula VIII

- 20 6.. A process as claimed in claim 3 wherein compound of formula II is further converted to a compound of formula IX, where R₃ is alkyl from 1 to 8 carbons, aryl or aralkyl, Ar is unsubstituted or substituted aryl or heteroaryl and X is a halogen.



Formula IX

- 5 7. A process as claimed in claim 6 wherein compound of formula
II is converted to compound of formula IX by reacting compound
of formula II with aqueous HBr solution or by reaction with
triphenyl phosphine and CBr₄.
8. A process as claimed in claim 6 or 7 wherein compound of
10 formula IX is further converted to a compound of formula VII,
where R₃ is alkyl from 1 to 8 carbons, aryl or aralkyl, Ar is
unsubstituted or substituted aryl or heteroaryl.



Formula VII

- 15 9. The product as claimed in claim 1, used in the synthesis of
atorvastatin, cerivastatin, pitavastatin, fluvastatin or rosuvastatin.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IN2004/000175

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl.?: C07D 305/12; C12P 17/02		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) SEE ELECTRONIC DATABASES BELOW		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN Files Registry, CA: molecular formulae; STN Files Medline, CA, WPIDS: keywords: Streptomyces, oleic, linolenic, statin and similar terms		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,598,089 (P. HADVARY ET AL) 1 July 1986, cited in the application See whole document	4-13
A	US 4,983,746 (P. BARBIER ET AL) 8 January 1991 See whole document	4
A	EISENREICH ET AL, "Tracer studies with crude U- ¹³ C-lipid mixtures: biosynthesis of the lipase inhibitor lipstatin", J Biol Chem, January 1997, Vol. 272, No. 2, p867-874 See whole document	4-13
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"&" document member of the same patent family</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		
Date of the actual completion of the international search 6 August 2004	Date of mailing of the international search report 19 AUG 2004	
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer L.F. MCCAFFERY Telephone No : (02) 6283 2573	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/IN2004/000175

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
US 4598089	AU 29478/84	CA 1247547	DK 308584				
	EP 0129748	ES 8600650	FI 842422				
	GR 82120	HU 34545	IL 72122				
	JP 60013777	LU 90302	LV 5747				
	MC 1602	MX 9203633	NO 842512				
	NZ 208521	PH 19704	PT 78777				
	ZA 8404558						
US 4983746	AU 51258/85	CN 85109209	DK 98792				
	DK 592585	EP 0189577	IL 77340				
	IL 92440	JP 61152664	NZ 214567				
	PH 22445	ZA 8509574					

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

END OF ANNEX

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.